Stockscreener 앱 받기
9.22
7.08%
0.61
전일 마감가:
$8.61
열려 있는:
$8.61
하루 거래량:
150.02K
Relative Volume:
0.51
시가총액:
$304.77M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+25.10%
1개월 성능:
-22.46%
6개월 성능:
-68.00%
1년 성능:
+0.00%
1일 변동 폭
$8.36
$9.26
1주일 범위
$7.14
$9.26
52주 변동 폭
$5.485
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
명칭
Oruka Therapeutics Inc
전화
650-606-7910
주소
855 OAK GROVE AVE., MENLO PARK
ORKA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
9.22 | 304.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-10-11 | 개시 | Stifel | Buy |
| 2024-10-07 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | Leerink Partners | Outperform |
| 2024-09-16 | 개시 | TD Cowen | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2018-02-27 | 개시 | Ascendiant Capital Markets | Buy |
| 2013-10-09 | 개시 | Dawson James | Buy |
모두보기
Oruka Therapeutics Inc 주식(ORKA)의 최신 뉴스
Oruka Therapeutics (ORKA) Projected to Post Quarterly Earnings on Thursday - Defense World
Vanguard Group Inc. Purchases 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) - The AM Reporter
Vanguard Group Inc. Acquires 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Acquired by Wellington Management Group LLP - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Charles Schwab Investment Management Inc. Takes Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Contrasting Achieve Life Sciences (NASDAQ:ACHV) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Fairmount Funds Management LLC Increases Stake in Oruka Therapeu - GuruFocus
Oruka Therapeutics Reports Strong 2024 Financial Results - TipRanks
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Oruka Therapeutics at Risk: Navigating Licensing Challenges and Partner Reliance - MSN
Comparing Oruka Therapeutics (NASDAQ:ORKA) & Celldex Therapeutics (NASDAQ:CLDX) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Issues Earnings Results - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Earns “Outperform” Rating from Wedbush - Defense World
We're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn Rate - Yahoo Finance
Sector Update: Health Care -March 07, 2025 at 03:38 pm EST - Marketscreener.com
Oruka Therapeutics Says ORKA-002 Preclinical Data Support Potential Extended Dosing Intervals - Marketscreener.com
Oruka Therapeutics: Buy Rating Backed by Strong Financials and Promising Clinical Progress - TipRanks
Oruka Therapeutics Announces Preclinical Data for ORKA-002 - GlobeNewswire
Stifel maintains Buy rating on Oruka Therapeutics stock, $49 target - Investing.com
Stifel maintains Buy rating on Oruka Therapeutics stock, $49 target By Investing.com - Investing.com Canada
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting - The Manila Times
Oruka Therapeutics Posts Q4 Net Loss -March 06, 2025 at 05:18 pm EST - Marketscreener.com
Oruka Therapeutics reports Q4 EPS (49c), consensus (98c) - TipRanks
Oruka Therapeutics Reports 2024 Financial Results and Progress on Psoriasis Pipeline Including ORKA-001 and ORKA-002 - Nasdaq
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Can Oruka's $394M War Chest Transform Autoimmune Disease Treatment? Key Pipeline Updates - StockTitan
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires $106,396.06 in Stock - MarketBeat
Insider Buying: Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires 88,794 Shares of Stock - MarketBeat
Oruka Therapeutics sees $1.41 million in stock purchases by Venrock Healthcare - Investing.com South Africa
Oruka Therapeutics sees $1.41 million in stock purchases by Venrock - Investing.com South Africa
Oruka Therapeutics (ORKA) to Release Earnings on Thursday - Defense World
Contrasting Virax Biolabs Group (NASDAQ:VRAX) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics to Present at Multiple March Investor Conferences - GlobeNewswire
Can This Clinical-Stage Biotech's March Conference Circuit Signal Major Developments? - StockTitan
Oruka Therapeutics (NASDAQ:ORKA) & Alpha Teknova (NASDAQ:TKNO) Head-To-Head Contrast - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
HC Wainwright Reaffirms Buy Rating for Oruka Therapeutics (NASDAQ:ORKA) - MarketBeat
Financial Fitness Check: Examining Oruka Therapeutics Inc (ORKA)’s Key Ratios - The Dwinnex
Oruka Therapeutics Inc (ORKA) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Oruka Therapeutics (NASDAQ:ORKA) Upgraded to Strong-Buy at Wolfe Research - MarketBeat
After Falling -15.24% During The Past Week, Should You Still Buy Oruka Therapeutics Inc (NASDAQ: ORKA)? - Marketing Sentinel
Vor Biopharma Inc (NASDAQ: VOR) Stock Falling -15.06% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Oruka Therapeutics (NASDAQ:ORKA) Now Covered by Analysts at Wolfe Research - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Shares Gap UpTime to Buy? - MarketBeat
Oruka Therapeutics inks exclusive license deal with Paragon - MSN
Oruka Therapeutics Inc (ORKA) 재무 분석
Oruka Therapeutics Inc (ORKA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Oruka Therapeutics Inc 주식 (ORKA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Par | 10% Owner |
Feb 13 '25 |
Buy |
11.63 |
14,950 |
173,868 |
4,059,634 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 12 '25 |
Buy |
11.86 |
8,971 |
106,396 |
4,044,684 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 11 '25 |
Buy |
10.95 |
9,593 |
105,043 |
4,035,713 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 10 '25 |
Buy |
10.90 |
574 |
6,257 |
4,026,120 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Aug 16 '24 |
Buy |
2.93 |
5,818 |
17,067 |
2,117,213 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 24 '24 |
Buy |
3.20 |
189,856 |
606,873 |
2,081,168 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 25 '24 |
Buy |
3.05 |
30,227 |
92,292 |
2,111,395 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 03 '24 |
Buy |
3.55 |
166,042 |
589,565 |
1,648,577 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 11 '24 |
Buy |
3.45 |
94,537 |
326,304 |
1,891,312 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 10 '24 |
Buy |
3.46 |
55,463 |
192,130 |
1,796,775 |
2.51%
자본화:
|
볼륨(24시간):